Superior Planning, LLC’s Oruka Therapeutics ORKA Stock Holding History

Superior Planning, LLC’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$21.4K	Buy	+257	New	+$24.2K	0.01%	671

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

Superior Planning, LLC's ORKA Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Oruka Therapeutics (ORKA) in Q3 2026: 257 shares worth $21.4K. The stake represents 0.01% of the portfolio and ranks #671 among its holdings.

136 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

Superior Planning, LLC held 257 shares of Oruka Therapeutics worth $21.4K as of Q3 2026.
Oruka Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Oruka Therapeutics made up 0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #671 holding.
136 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.